Evidence mapPaperPMID 39723590Full record

ReviewNanomedicine (London, England)2025

Nanotoxicology: developments and new insights.

Henry N Abonyi, Ikechukwu E Peter, Akachukwu M Onwuka, Paul A Achile, Chinonso B Obi, Maureen O Akunne, Paul M Ejikeme, Samson Amos, Theophine C Akunne, Anthony A Attama and 1 more

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Henry N AbonyiNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Ikechukwu E PeterNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Akachukwu M OnwukaNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Paul A AchileNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Chinonso B ObiNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Maureen O AkunneNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Paul M EjikemeNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Samson AmosNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Theophine C AkunneNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.
Anthony A AttamaNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.ORCID 0000-0002-5751-2280
Peter A AkahNanotheranostics Drug Discovery Research Group, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of nanoparticles (NPs) in treatment of diseases have increased exponentially recently, giving rise to the science of nanomedicine. The safety of these NPs in humans has also led to the science of nanotoxicology. Due to a dearth of both readily available models and precise bio-dispersion characterization techniques, nanotoxicological research has obviously been constrained. However, the ensuing years were notable for the emergence of improved synthesis methods and characterization tools. Major advances have been made in linking certain physical variables, paralleling improvements in characterization size, shape, or coating factors to the resulting physiological reactions. Although significant progress has been a contribution to the development of nanotoxicology, however, it faces numerous difficulties and technical constraints distinct from those of conventional toxicological assessment as it attempts to improve the therapeutic effects of medicines. Determining thorough characterization standards, standardizing dosimetry, assessing the kinetics of ions dissolving and enhancing the accuracy of

Indexed as

NanomedicineNanoparticlesAnimalsHumansParticle SizeToxicity Testscharacterizationin vitro-in vivo correlationNanotoxicologyNPsstandardizing dosimetry

Identifiers

PMID39723590
PMCPMC11731054

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.